Skip to main content

Table 1 Effects of fulvestrant, HRGβ1 or a combination of the two treatments on immunocytochemically determined nuclear Ki-67 positivity in MCF-7, T47D, BT474 and MDAMB361 cells

From: Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

  Nuclear Ki-67 positivity, %
Cell type Control Fulvestrant HRGβ1 Fulvestrant + HRGβ1
MCF-7 97 ± 1.2 55 ± 4.5* 90 ± 0.4 89 ± 1.8†
T47D 80 ± 2.2 41 ± 3.6* 63 ± 2.7** 49 ± 5.8
BT474 38 ± 2.2 13 ± 1.3* 48 ± 2.2*** 50 ± 1.3††
MDAMB361 82 ± 0.9 38 ± 1.8* 59 ± 2.2** 71 ± 2.2††
  1. HRGβ1, heregulin β1. Nuclear positivity percentage values are expressed as means ± standard deviation of the assessment of six fields of view per coverslip in triplicate experiments.
  2. *P < 0.001 versus control, **P < 0.05 versus control, ***P < 0.01 versus control, P < 0.01 versus fulvestrant, ††P < 0.001 versus fulvestrant.